Kornimate/medical-research-clean huggingface dataset:
intracellular phosphate concentration evolution during hemodialysis by mr spectroscopy

Conditions: End-Stage Renal Disease (ESRD)

Summary: end-stage renal disease is associated with hyperphosphatemia due to a decrease of renal phosphate excretion. this hyperphosphatemia is associated with an increase of cardiovascular risk and mortality. thus, three therapeutic options have been developed: dietary restriction, administration of phosphate binders and phosphorus clearance by hemodialysis (hd). during a standard hd session, around 600 to 700mg phosphate is removed from the plasma, whereas it contains only 90 mg inorganic phosphate (pi); 85% of phosphate is stored in bones and teeth in hydroxyapatite form, 14% is stored in the intracellular space (90% organic phosphate and 10% pi), and 1% remains in the extracellular space. currently, the source of pi cleared during hd remains to be determined. phosphorus (31p) magnetic resonance spectroscopy allows reliable, dynamic and non-invasive measurements of phosphate intracellular concentration. the investigator's team recently published data obtained in anephric pigs, suggesting that phosphate intracellular concentration increases during a hd session. in parallel, we showed that atp intracellular concentration decreased. these results suggest that the source of pi cleared during hd could be located inside the cell. in this study, investigators will measure intracellular phosphate and atp concentrations and intracellular potential of hydrogen (ph) evolution during hemodialysis in 12 patients suffering from end-stage renal disease by mr spectroscopy. if these results were confirmed in humans, it could explain, at least in part, hd intolerance in some patients and would lead to modify therapeutic approaches of hyperphosphatemia, for example, by modifying hd sessions time.


Eligibility criteria:
inclusion criteria: * patient suffering from end-stage renal disease, treated by chronic hemodialysis since at less 6 months * phosphatemia (at the start of the session) ≥ 1,5 mmol/l and ≤ 3 mmol/l * written consent signed exclusion criteria: * major subject protected by law * prisoners or subjects who are involuntarily incarcerated * denutrition (weight loss ≥ 5 kg in one months/10 kg in 6 months, body mass index (bmi) ≤ 21 kg/m2, albuminemia ≤ 35 g/l) * obesity (bmi ≥ 30 kg/m2) * phosphatemia at the start of the dialysis \ 3 mmol/l * secondary hyperparathyroidism with parathormone (pth) ≥ 1000 pg/ml * adynamic osteopathy (pth ≤ 50 pg/ml) * hypoparathyroidism with a history of parathyroidectomy * hemoglobin ≤ 100 g/l * contraindication to heparin * temporary vascular access * contraindication to resonance magnetic spectroscopy (pacemaker or insulin pump, metallic valvular prosthesis, valvular prosthesis not compatible with resonance magnetic spectroscopy, dental appliance, intracerebral clip, claustrophobic subject). * simultaneous participation to another research protocol * patient not affiliated to a social security system

Keywords: esrd hemodialysis phosphate atp magnetic resonance spectroscopy
suprapatellar versus infrapatellar nailing in tibial fractures: a pilot study

Conditions: Tibial Fractures

Summary: this study compares two techniques for the fixation of tibial fractures. the techniques are the suprapatellar (above knee)or infrapatellar (below knee) approach to tibial intramedullary nailing. null hypothesis: there is no difference in 1) residual post-operative pain levels, 2)knee function, 3) healing and alignment of the tibia, or 4) trochlear changes in the patello-femoral cartilage between patients who are randomized to receive tibial nail insertion through either a suprapatellar nail entry portal or a standard patellar tendon approach.

patients undergoing tibial fracture repair will be consented and randomized into one of the two techniques, with arthroscopic photos taken before and after nail insertion to study the condition of the patello-femoral cartilage. enrolled patients will be followed for one year in clinic.

Eligibility criteria:
inclusion criteria: * tibial shaft fractures amenable and indicated for repair with intramedullary nails, with or without the use of reaming * acute tibial fractures within 4 weeks of injury * closed or open tibial fractures after appropriate irrigation and debridement * fractures must be within metaphyseal/diaphyseal junctures defined as middle 3/5 of tibia * skeletally mature patient * age 18 and above. exclusion criteria: * tibial shaft fractures that require articular reconstruction with plates * any tibial fracture extending \> 1 cm into the proximal or distal 1/5 of tibia * tibial plateau fractures * pilon fractures * periprosthetic fractures * non-unions * prior knee surgery * history of gout or rheumatoid or osteoarthritis * concomitant injury to same limb (including any traumatic injury to ipsilateral knee, femur or foot, and knee dislocation) * spinal injury * prisoner or high likelihood of incarceration * not likely to follow-up in the estimation of surgeon * pregnant females

Keywords: tibia suprapatellar
clinical and surgical outcomes of thyroid carcinoma in children and adolescents

Conditions: Pediatric and Adolescent Differentiated Thyroid Carcinoma; SEER Database Analysis

Summary: this study aims to investigate the differences in clinical characteristics, causes of death, long-term survival, and surgical approaches between pediatric and adolescent follicular and papillary carcinoma by exploring data from the seer database. the research is designed as a retrospective cohort study, primarily focused on collecting and comparing data to identify key disparities and outcomes between these two patient groups. it is anticipated that the findings will provide valuable insights into the management and prognosis of these cancers in younger populations, contributing to more targeted and effective treatment strategies.

this study is a retrospective cohort analysis aimed at elucidating the differences between pediatric and adolescent patients diagnosed with follicular and \[specific type\] carcinoma, utilizing data sourced from the seer (surveillance, epidemiology, and end results) database. the focus of the research is on a comprehensive comparison of various clinical aspects, including demographic characteristics, tumor features, treatment modalities, and survival outcomes. key areas of investigation include the examination of clinical characteristics such as tumor size, location, and stage at diagnosis, as well as treatment approaches including surgery types and their impact on patient outcomes. additionally, the study will assess the causes of death and overall survival rates among these young patients, aiming to identify any significant prognostic factors. by leveraging the robust and extensive data available in the seer database, this study seeks to uncover critical insights into the management of follicular and \[specific type\] carcinoma in pediatric and adolescent populations. the findings are expected to contribute to the development of more tailored and effective therapeutic strategies, ultimately improving long-term survival and quality of life for affected patients.

Eligibility criteria:
inclusion criteria: * pathologically confirmed diagnosis of follicular thyroid carcinoma (ftc) or papillary thyroid carcinoma (ptc). * age range: pediatric and adolescent patients (ages 1-18 years). exclusion criteria: * patients with incomplete survival and clinical information.
the neoadjuvant treatment modalities in patients with locally advanced esophageal squamous cell carcinoma (neo-ec）

Conditions: Esophageal Carcinoma

Summary: the prognosis and safety of patients with locally advanced esophageal squamous cell carcinoma were compared with different neoadjuvant therapy modes in multi-cancer centers in china

neoadjuvant chemoradiotherapy or neoadjuvant chemotherapy combined with surgery are the main treatment methods for patients with locally advanced esophageal squamous cell carcinoma, but some patients still have local recurrence or distant metastasis after surgery. in the era of immunotherapy, immune checkpoint inhibitor monotherapy or combined chemotherapy has become the first-line and second-line standard treatment for recurrent or metastatic esophageal cancer and has been recommended by nccn guidelines. however, relevant studies on immunotherapy's participation in neoadjuvant therapy have shown good results, but it is still in its initial stage, and its efficacy needs further research and discussion.thus, we compared the prognosis and safety of patients with locally advanced esophageal squamous cell carcinoma who received different neoadjuvant therapy before surgery, including neoadjuvant chemoradiotherapy, neoadjuvant chemotherapy, neoadjuvant chemotherapy combined with immunotherapy, and neoadjuvant chemoradiotherapy combined with immunotherapy in several cancer centers in china.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years, male or female; 2. kps score (kps) ≥70; 3. esophageal squamous cell carcinoma confirmed by histopathology; 4. clinical stage ct1b-4an+m0,t3-4an0m0; 5. surgical resection was performed after 2\~4 cycles of neoadjuvant therapy. 6. expected survival \> 6 months. exclusion criteria: 1. have a history of other malignancies (except for cancer in situ that has been cured and other malignancies that have been cured for more than 5 years); 2. there are contraindications of immunotherapy or chemoradiotherapy; 3. inability to tolerate or refuse surgery; 4. distant metastasis has occurred;

Keywords: esophageal carcinoma neoadjuvant therapy prognosis
inhibitor masking device & sodium channel, voltage gated, type ix alpha subunit (scn9) gene expression

Conditions: Tinnitus

Summary: to evaluate the effectiveness of the inhibitor™ tinnitus masking device. to determine if there is a higher incident of expression of the sodium channel, voltage gated, type ix alpha subunit (scn9) gene in those subjects with disturbing tinnitus than subjects that are not disturbed by tinnitus.

up to 50 million americans have tinnitus on a regular basis with between 2-3 million suffering from tinnitus where it affects daily living. the inhibitor™ tinnitus masking device is a new tinnitus treatment device recently available in the united states for use of temporary relief of tinnitus. the device emits an ultra high frequency sound for 60 seconds via bone conduction when applied to the mastoid. patients reporting tinnitus will be provided the opportunity to demonstrate the device to observe any changes in their tinnitus. the device may be demonstrated up to 5 times. the investigators will be recording the the degree and duration of change in tinnitus perception following treatment with the inhibitor™ tinnitus masking device. patients may provide a genetic sample (typically via saliva sample) to look for expression of a particular genetic marker that may be associated with tinnitus. the investigators will be collect samples from both people with tinnitus and those without tinnitus to use as a control.

Eligibility criteria:
inclusion criteria: * over 18 years, * has tinnitus exclusion criteria: * pacemaker, * pregnancy, * metal implants in head or neck, * thrombosis, migraines/headaches, * metal bonded retainer, surgeries within the last 6 months which patient is still recovering from, * any medical reason your physician would advise against the use of this device, * under 18 years

Keywords: tinnitus inhibitor device scn9 gene ringing in the ears milwaukee medical college of wisconsin
same day diagnosis of extrapulmonary tb (tb serositis and tb meningitis).

Conditions: Tuberculosis, Extrapulmonary

Summary: extrapulmonary tb (eptb) accounts for nearly 30% of tb cases in hiv endemic settings, such as south africa. the diagnosis of extrapulmonary tb is complicated by the poor performance of gene xpert and tb culture in extrapulmonary fluid (30-50% sensitive), as well as the poor specificity of ada. we can therefore not reliably use these tests to diagnose eptb as effectively as we use them in sputum samples. the current best practice for diagnosing pleural tb is to perform a pleural biopsy, which is both invasive and costly. a rapid, easy to use test is needed to allow accurate and fast diagnosis of eptb. interferon-gamma is released at high concentrations in extrapulmonary fluid in active eptb. antrum biotech has developed the irisa-tb assay (validated and sahpra licenced) for the diagnosis of eptb. the study will assess the real-world performance of irisa-tb compared to ada, gene xpert, and tb culture when used to diagnose eptb. we will evaluate irisa-tb's performance in the following patient groups: * suspected tb pleural effusion (n= 650) * suspected tb pericardial effusion (n= 280) * suspected tb peritonitis (n= 200) * suspected tb meningitis (n = 1040) as part of our evaluation, we will ask clinicians who treat these patients to provide their feedback on irisa-tb. we will ask them to indicate to what extent the irisa-tb test helped them to make treatment decisions. finally, we will conduct an economic assessment to determine the true cost of diagnosing and treating eptb to the health system and patients, and we will determine how irisa-tb could potentially result in cost savings.


Eligibility criteria:
inclusion criteria: 1. male or female participants 18 years and over attending health care facility with symptoms of tb. 2. serosal or csf fluid sample provided to nhls with sufficient volume to perform soc tests + 1ml. 3. patients in whom extrapulmonary tb is part of the treating clinicians' differential diagnosis. exclusion criteria: 1. volunteers who refuse to sign informed consent and/or provide clinical details (proxy consent will be obtained for participants who are incapacitated, with a follow up consent when they have recovered their capacity to consent) 2. patients with current significant history of substance or alcohol abuse that may impact study visits. 3. patients who are unable to communicate by telephone or who do not have a current active traceable contact number. 4. patients not willing to undergo an hiv test. 5. patients whose fluid sample volumes are insufficient to perform standard of care testing in addition to irisa-tb 6. positive sputum gxp within 2 weeks prior to serosal fluid or csf sampling.

Keywords: tuberculosis interferon-gamma tuberculosis diagnostics
safe mothers, safe children initiative

Conditions: PTSD; Depression; Child Maltreatment

Summary: the purpose of this study is to assess the efficacy of the combined interventions, skills training in affective and interpersonal regulation (stair) and parent-child interaction therapy (pcit) or p-stair, for treating maternal ptsd and reducing maltreatment recidivism.

this study is a two-arm randomized controlled trial (rct): p-stair (23 sessions) vs. supportive counseling (sc) (23 sessions). eligible cases are randomized to p-stair and sc in a 1:1 ratio. participants will be mothers receiving family preservation services (fps), with a child in the age range of 1-8 years old, and ptsd (with/without depression). symptom progress will be measured at pre-treatment, two in-treatment assessments (9 weeks and 16 weeks), post-treatment, and at a 6-month follow-up.

Eligibility criteria:
inclusion criteria: * receiving preventive services * meeting a severity score of 28 or higher or probable dsm-5 diagnostic criteria for ptsd (pds-5) * having 1-8-year-old child * being the legal guardian for the child with physical and legal custody * being able to read, write, and speak english or spanish exclusion criteria: * having suicidal ideation present in the past month prior to pre-assessment or reports of a suicide attempt in the past year (scid-5) * meeting a diagnosis of severe substance or alcohol use disorder (≥ 6 symptoms on scid) and not in early remission (≥3 months without meeting any substance or alcohol use disorder criteria (except craving) * having current or active symptoms of psychosis in the past month * having a disability affecting communication, such as deafness * having an index child with a developmental condition that impedes cognitive and/or physical functioning, e.g. autism * having an index child with current symptoms or diagnosis of psychosis as defined by the dsm-5 in the past 3 months * experiencing current or history of intimate partner violence (ipv) or family violence: if there is a history of ipv/family violence and the relationship is no longer active, the relationship must have ended for at least ninety days with no intention of restarting; if there is a history of ipv/family violence, but the relationship is ongoing, there must not have been an ipv/family violence event for at least one year
action observation treatment in parkinson's patients

Conditions: Parkinson

Summary: the aim of the study is to assess the role of action observation treatment (aot) and motor imagery (mi) in the rehabilitation of parkinson's disease patients, as compared to a control condition. main outcome measures will be the results in two functional scales (fim, updrs) and kinematics parameters obtained from gait analysis. data at two months and six months follow up, respectively, will be also collected.


Eligibility criteria:
inclusion criteria: * parkinson disease patients on hoehn and yahr 3-4 exclusion criteria: * mini-mental state examination \< 24 * fluent aphasic patients * apraxia * neglect * major neuropsychiatric disorders

Keywords: action observation treatment motor imagery randomized controlled study
use of fragmin in hemodialysis

Conditions: Chronic Renal Failure

Summary: the study will determine if the fragmin dose can be adjusted to suit the clinical needs of patients during dialysis.


Eligibility criteria:
inclusion criteria: * chronic renal failure on hemodialysis exclusion criteria: * significant comorbidities that would prevent a patient from completing the trial

Keywords: fragmin dalteparin hemodialysis anticoagulation renal failure
the study compare and evaluate the safety and pk data of a single dose administration of 'ad-115a' or 'ad-1151'

Conditions: Gastric Ulcer

Summary: the study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'ad-115a' or 'ad-1151' in healthy adults.

a randomized, open-label, single-dose, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of ad-115a and the administration of ad-1151 for healthy subjects in fasting state

Eligibility criteria:
inclusion criteria: * the age equal to or greater than 19 in healthy volunteers at the time of screening visit * body mass index (bmi) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit exclusion criteria: * individuals who have taken drugs that induce (e.g., barbiturates) or inhibit drug-metabolizing enzymes within 30 days prior to the start of the study (first dosing day), or have taken drugs that may affect this study within 10 days prior to the start of the study (first dosing day) * other exclusions applied
a study to evaluate tmi-358 in the treatment of distal subungual onychomycosis

Conditions: Distal Subungual Onychomycosis

Summary: the purpose of this study is to determine if a local treatment is effective for the treatment of toenail fungus (distal subungual onychomycosis).


Eligibility criteria:
inclusion criteria: * male or female, 18 to 75 years of age, inclusive * diagnosed with distal subungual onychomycosis (dso) of the toenails * great toe(s) with intact skin and intact neurologic functions * great toenail(s) free of nail polish * at least one target great toe which has: * 25 to 75% involvement of the area of the nail unit (including destroyed or missing parts of the nail plate) * at least 2 mm of uninvolved nail growth as measured from the proximal nail fold to the most proximal point to the disease process and with no lunular involvement * nail unit hyperkeratosis at the most distal edge which measures no greater than 3 mm * a positive koh and culture exclusion criteria: * any significant disease of the hepatic, renal, endocrine (including diabetes mellitus), immune systems, or other health conditions which could interfere with or confound the results of study assessments * pre-existing chronic foot pain, neurologic deficit or skin disease/injury in treated foot * in the case of female subjects, are pregnant, nursing, or planning to become pregnant within the study period * history of clinically significant abnormal laboratory values, including liver function test results equal to or greater than 2 x the upper limit of normal * disease-like psoriatic toenails, significant toenail abnormalities/dystrophies, toenail injuries or any other condition in the toenail which could interfere with study evaluations (e.g., prevent obtaining normal appearing nail, after clearing of onychomycosis, due to chemical damage, genetic or pigmentary disorders, etc.) * have white superficial onychomycosis, proximal subungual onychomycosis, yellow spikes, or dermatophytoma * have paronychia * have a history of chronic alcohol or drug abuse

Keywords: distal subungual onychomycosis
determinants of alpha-aminoadipic acid (2-aaa) and relationship to diabetes: study 2

Conditions: Healthy

Summary: this study aims to assess the effect of controlled dietary lysine intake on plasma and urine α-aminoadipic acid (2-aaa).

diabetes is an important health concern worldwide. it is associated with significantly increased mortality as well as high incidence of co-morbidities. unfortunately, treatment efficacy and successful disease management is highly variable among treated patients, and this is partly due to the fact that diabetes has multiple underlying causes most of which are still unknown. a newly identified biomarker, α-aminoadipic acid (2-aaa), has the potential to successfully predict the development of diabetes in humans, even before the development of other known risk markers. however, little is known about the function of 2-aaa; it is unclear whether 2-aaa itself causes the development of diabetes or if it is a biomarker for altered metabolic processes that then lead to diabetes. the aim of the first phase of the study was to measure plasma 2-aaa levels from healthy individuals from the general population to identify subjects with high or low 2-aaa. now in the second phase of the study, 80 subjects with high or low 2-aaa will be invited to participate in a dietary lysine modification study to access the effect of controlled lysine intake on plasma and urine 2aaa. participants will be asked to complete two one-week dietary interventions. subjects will be screened and consented via email, online, or phone. each subject will be required to come to vanderbilt university medical center for four study visits, at which the study team will obtain a blood sample, a urine sample, stool sample, vital signs, waist and hip circumference, and 1-3 surveys will be completed if the subject did not complete them prior to the visit. each subject that completes the entire study visit will be compensated $250. dna samples will be obtained to allow for identification of genetic predictors of 2-aaa levels. some individuals may be asked to return for a future follow-up study.

Eligibility criteria:
inclusion criteria: * prior participant in 2-aaa screening study. * identified as eligible due to high or low plasma 2-aaa, in the absence of hyperglycemia, as defined by study team. exclusion criteria: * individuals who currently use tobacco products. * use of prescription or over-the-counter medications or dietary supplements which could modulate levels of 2-aaa and unwilling to discontinue use (from 24 hours prior to first study visit until completion of study). hormonal birth control is acceptable. * follow a severely restricted diet or have food allergies, which would preclude adherence to study diet. * newly diagnosed disease (since screening visit), including cardiovascular, renal, or liver disease, or diabetes mellitus. * individuals who are pregnant or lactating * inability to provide written or electronic informed consent * inability to fast for 8 hours